Casgevy™ (exagamglogene autotemcel) – New orphan indication
January 16, 2024 - Vertex announced the FDA approval of Casgevy (exagamglogene autotemcel), for the treatment of patients aged 12 years and older with transfusion-dependent β-thalassemia (TDT).
Download PDF
